Business News • PR NewsWire • Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

NEW YORK, Nov. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that it has closed its previously...

View More : https://www.prnewswire.com:443/news-releases/oramed-announces-closing-of-50-million-registered-direct-offering-of-common...

Releted News by prnewswire

Medical Cannabis Market to Reach $53.88 Bn, Globally, by 2030 at 23.6% CAGR: Allied Market Research

AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Deliver Talk at World Immunotherapy Congress Europe

Redfin to Present at 1st Annual Needham Consumer Tech / E-Commerce Virtual Conference

Redfin to Attend 2021 Berenberg US CEO Conference